Cargando…
Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938635/ https://www.ncbi.nlm.nih.gov/pubmed/36819977 http://dx.doi.org/10.1093/immadv/ltad002 |
| _version_ | 1784890674713198592 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9938635 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99386352023-02-19 Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor Immunother Adv Correction Oxford University Press 2023-02-18 /pmc/articles/PMC9938635/ /pubmed/36819977 http://dx.doi.org/10.1093/immadv/ltad002 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correction Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title | Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title_full | Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title_fullStr | Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title_full_unstemmed | Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title_short | Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor |
| title_sort | correction to: characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against tim-3 receptor |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938635/ https://www.ncbi.nlm.nih.gov/pubmed/36819977 http://dx.doi.org/10.1093/immadv/ltad002 |